Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy
Sponsor: AGO Study Group
This PHASE3 trial investigates Ovarian Cancer and is currently completed. AGO Study Group leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Sep 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AGO Study Group
- European Organisation for Research and Treatment of Cancer - EORTC
- NCIC Clinical Trials Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barrie, Canada , Brampton, Canada , Calgary, Canada , Charlottetown, Canada , Chicoutimi, Canada , Duluth, United States , Edmonton, Canada , Fleurimont, Canada , Greater Sudbury, Canada , Greenfield Park, Canada and 42 more locations